Cellectis
Open
$3.13
Prev. Close
$3.13
High
$3.13
Low
$3.09
Market Snapshot
$220.64M
-3.3
-0.47
$49.22M
229
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 229 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 229 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Recently from Cashu
Cellectis Advances Gene Editing Amid Industry Challenges and Market Trends in Biotechnology
Earning Insights Amidst Industry Challenges: Focus on Cellectis and Gene Editing Cellectis, a pioneering player in the gene editing landscape, remains at the forefront of innovation in biotechnology.…
Cellectis Advances Gene Editing with TALEN™ and Off-the-Shelf CAR-T Cell Therapies
Cellectis' Innovations in Gene Editing: A Strategic Focus on Cell and Gene Therapies Cellectis, a leader in the field of gene editing, continues to pioneer innovative solutions that harness the power…
Cellectis: Request for Content to Summarize.
I apologize, but it appears there is no content provided for summarization. Please provide the specific details or text you'd like me to summarize, and I'll be glad to assist you!
Cellectis Advances Gene Therapy with Innovative CssDNA Technology for Enhanced Treatment Options
Cellectis Pioneers Gene Therapy with Innovative CssDNA Technology Cellectis A/S recently makes headlines in the field of gene therapy with its groundbreaking publication in Nature Communications, deta…